Investor Presentaiton
Major R&D Pipeline: Next Wave
DS-1055 (JP/US)
Anti-GARP antibody
Solid tumors
DS-1594 (US)
Menin-MLL binding inhibitor
AML, ALL
DS-9606 (US/EU)
Target undisclosed ADC
Solid tumors
DS-1103
Anti-SIRPA antibody
Phase 1
HER2 expressing or mutant advanced metastatic solid
tumors, HER2 low BC (ENHERTUⓇ combo)
DS-3939
Anti-TA-MUC1 ADC
Solid tumors (in prep.)
DS-1471
Anti-CD147 antibody
Solid tumors (in prep.)
DS-7011 (US)
Anti-TLR7 antibody
Systemic lupus erythematosus
DS-2325 (US)
KLK5 inhibitor
Netherton syndrome
+00
Phase 2
Valemetostat (DS-3201)(JP/US/EU/Asia)
EZH1/2 inhibitor
PTCL
Valemetostat (DS-3201) (EU)
EZH1/2 inhibitor
BCL
DS-1001 (JP)
Mutant IDH1 inhibitor
Glioma
DS-1211 (US/EU)
TNAP inhibitor
Pseudoxanthoma elasticum
As of Jul 2023
Phase 3
Filed
Pexidartinib (JP/Asia)
Quizartinib (EU)
CSF-1/KIT/FLT3 inhibitor
Tenosynovial giant cell tumor
FLT3 inhibitor
AML 1L
Esaxerenone (JP)
MR blocker
Diabetic nephropathy
VN-0102/JVC-001 (JP)
Measles mumps rubella combined vaccine
DS-5670 (JP)
COVID-19 mRNA vaccine (original strain), COVID-19
(primary vaccination, 12 to 17 aged children)
Mirogabalin (CN)
a28 ligands
Diabetic peripheral neuropathic pain
DS-5670 (JP)
COVID-19 mRNA vaccine (original strain)
COVID-19 (booster vaccination)
DS-5670 (JP)
COVID-19 mRNA vaccine (mutant strain), COVID-19
(primary vaccination, 5 to 11 aged children) (in prep.)
VN-0200 (JP)
RS virus vaccine
RS virus infection
DS-5670 (JP)
COVID-19 mRNA vaccine (mutant strain)
COVID-19 (booster vaccination, 12 years old and over)
DS-5670 (JP)
COVID-19 mRNA vaccine (mutant strain), COVID-19
(booster vaccination, 5 to 11 aged children)
Oncology
Specialty medicine
Vaccine
Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
"
SAKIGAKE Designation (JP)
Fast Track Designation (US)
Orphan drug designation (designated in at least one country/region among JP, US and EU)
Breakthrough Designation (US)
Rare Pediatric Disease Designation (US)
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, LBCL: large B cell lymphoma, PTCL: peripheral T-cell lymphoma
Daiichi-Sankyo
36View entire presentation